RPGL—54

RPG Life Sciences Ltd

PharmaceuticalsVerified

RPG Life Sciences has a revenue of INR 1,654.20 million and a net income of INR 267.60 million, indicating a net margin of 16.18%. The company's operating income of INR 337.80 million suggests a strong operating margin of 20.42%, which is a key indicator of its operational efficiency. The company's profitability is further reflected in its gross profit of INR 1,104.10 million, translating to a gross margin of 66.75%. These metrics suggest that RPG Life Sciences is effectively managing its production and operational costs, which is a positive sign for its financial health. RPG Life Sciences operates primarily in the Indian market, and its revenue is concentrated in this region. The company does not disclose specific segment or geographic breakdowns in its latest financials, making it difficult to assess the diversification of its revenue streams. The company's growth trajectory is not clearly defined in the latest financial data, as there are no specific projections or historical growth rates provided. However, the current revenue and net income figures suggest a stable financial position. The risk assessment for RPG Life Sciences indicates a low dilution risk, with no significant dilution potential identified in the latest financial data. However, the liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. Recent events and filings for RPG Life Sciences do not indicate any major changes or risks that would significantly impact its financial position. The company's latest financial data does not include any recent events or transcripts that would provide additional insight into its operations or strategic direction.

30-day price · RPGL+414.90 (+22.1%)

Low$1840.40High$2524.90Close$2292.50As of17 May, 00:00 UTC

Profile

CompanyRPG Life Sciences Ltd

TickerRPGL.NS

SectorHealthcare

BusinessPharmaceuticals & Medical Research

Industry groupPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI analysis

Business. RPG Life Sciences Ltd is a pharmaceutical company that develops and markets a range of healthcare products, primarily in the Indian market.

Classification. RPG Life Sciences is classified under the Pharmaceuticals industry within the Healthcare economic sector, with a classification confidence of 0.92.

Key takeaways

RPG Life Sciences has a strong net margin of 16.18%, indicating effective cost management and profitability.
The company's gross margin of 66.75% suggests efficient production and operational processes.
RPG Life Sciences' revenue is primarily concentrated in the Indian market, with no disclosed segment or geographic diversification.
The company's liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.
RPG Life Sciences has a low dilution risk, with no significant dilution potential identified in the latest financial data.
--
## RATIONALES
```json

Financial snapshot

PeriodHA-latest

CurrencyINR

Revenue$1.65B

Gross profit$1.10B

Operating income$337.8M

Net income$267.6M

R&D—

SG&A—

D&A—

SBC—

Operating cash flow—

CapEx—

Free cash flow—

Total assets—

Total liabilities—

Total equity—

Cash & equivalents—

Long-term debt—

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY-4$4.40B$707.0M$514.8M$312.8M

FY-3$5.13B$879.7M$676.4M$345.3M

FY-2$5.82B$1.11B$876.6M$156.5M

FY-1$6.53B$2.21B$1.83B$1.42B

FY0$7.08B$1.30B$1.15B$316.0M

PeriodGross %Op %Net %FCF %

FY-4————

FY-3————

FY-2————

FY-1————

FY0————

PeriodAssetsEquityCashDebt

FY-4$3.45B$2.56B$569.4M—

FY-3$4.19B$3.08B$248.2M—

FY-2$5.13B$3.75B$170.0M—

FY-1$6.58B$5.31B$260.0M—

FY0$7.93B$6.05B$1.92B—

PeriodOCFCapExFCFSBC

FY-4$647.5M-$239.5M$312.8M—

FY-3$908.1M-$327.3M$345.3M—

FY-2$943.6M-$692.3M$156.5M—

FY-1$778.6M-$360.3M$1.42B—

FY0$565.0M-$653.6M$316.0M—

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

FQ-7$1.65B$337.8M$267.6M—

FQ-6$1.72B$133.2M$42.0M—

FQ-5$1.73B$437.0M$349.3M—

FQ-4$1.43B$1.30B$1.17B—

FQ-3$1.69B$303.3M$262.9M—

FQ-2$1.82B$450.3M$368.5M—

FQ-1$1.80B$259.6M$221.3M—

FQ0$1.77B$281.9M$299.0M—

PeriodGross %Op %Net %FCF %

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

PeriodAssetsEquityCashDebt

FQ-7————

FQ-6$5.54B$3.79B$340.3M—

FQ-5————

FQ-4$6.58B$5.31B$1.40B—

FQ-3————

FQ-2$7.06B$5.54B$1.32B—

FQ-1————

FQ0$7.93B$6.05B$1.92B—

PeriodOCFCapExFCFSBC

FQ-7————

FQ-6$463.3M-$242.0M——

FQ-5————

FQ-4$778.6M-$360.3M——

FQ-3————

FQ-2$112.7M-$319.7M——

FQ-1————

FQ0$565.0M-$653.6M——

Valuation

Market price—

Market cap—

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book—

Net cash—

Current ratio—

Debt/Equity—

ROA—

ROE—

Cash conversion—

CapEx/Revenue—

SBC/Revenue—

Asset intensity—

Dilution ratio0.0%

Risk assessment

Dilution riskLow

Liquidity riskUnknown

Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).

Industry benchmarks

Activity: Pharmaceuticals · cohort 779 companies

MetricRPGLActivity

Op margin20.4%7.7% medp25 -2.4% · p75 15.5%top quartile

Net margin16.2%5.9% medp25 -3.8% · p75 12.8%top quartile

Gross margin66.7%45.5% medp25 31.1% · p75 62.9%top quartile

R&D / revenue—529.2% medp25 465.2% · p75 593.2%

CapEx / revenue—-7.0% medp25 -14.9% · p75 -3.2%

Debt / equity—25.0% medp25 3.8% · p75 63.3%

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

Company fundamentalsperiod FQ-7 · history via verified-market-data

no public URL

2026-05-07 07:55 UTC#9c64c1fe

Source: analysis-pipeline (hybrid)Generated: 2026-05-29 06:16 UTCJob: 7b877251